{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:29:07Z","timestamp":1787905747475,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00345-018-2349-9","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T08:07:56Z","timestamp":1527322076000},"page":"2027-2034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Salvage topical therapy for upper tract urothelial carcinoma"],"prefix":"10.1007","volume":"36","author":[{"given":"Adithya","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Wagenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"issue":"3","key":"2349_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35(3):379\u2013387","journal-title":"World J Urol"},{"issue":"8","key":"2349_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/ncpuro0875","volume":"4","author":"JD Raman","year":"2007","unstructured":"Raman JD, Scherr DS (2007) Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol 4(8):432\u2013443","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"2349_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.eururo.2008.01.006","volume":"53","author":"R Zigeuner","year":"2008","unstructured":"Zigeuner R, Pummer K (2008) Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol 53(4):720\u2013731","journal-title":"Eur Urol"},{"issue":"6","key":"2349_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","volume":"63","author":"M Roupret","year":"2013","unstructured":"Roupret M, Babjuk M, Comperat E et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059\u20131071","journal-title":"Eur Urol"},{"issue":"1","key":"2349_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.juro.2015.02.081","volume":"194","author":"M Mork","year":"2015","unstructured":"Mork M, Hubosky SG, Roupret M et al (2015) Lynch syndrome: a primer for urologists and panel recommendations. J Urol 194(1):21\u201329","journal-title":"J Urol"},{"key":"2349_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1464-410X.2005.05210.x","volume":"95","author":"GB Johnson","year":"2005","unstructured":"Johnson GB, Fraiman M, Grasso M (2005) Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int 95:110\u2013113","journal-title":"BJU Int"},{"issue":"5","key":"2349_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupret","year":"2015","unstructured":"Roupret M, Babjuk M, Comperat E et al (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68(5):868\u2013879","journal-title":"Eur Urol"},{"issue":"5","key":"2349_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0022-5347(01)64793-1","volume":"157","author":"FX Keeley","year":"1997","unstructured":"Keeley FX, Bibbo M, Bagley DH (1997) Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 157(5):1560\u20131565","journal-title":"J Urol"},{"issue":"3","key":"2349_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/end.2017.0915","volume":"32","author":"G Musi","year":"2018","unstructured":"Musi G, Mistretta FA, Marenghi C et al (2018) Thulium laser treatment of upper urinary tract carcinoma: a multi-institutional analysis of surgical and oncological outcomes. J Endourol 32(3):257\u2013263","journal-title":"J Endourol"},{"issue":"9","key":"2349_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","volume":"17","author":"R Veeratterapillay","year":"2016","unstructured":"Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C (2016) High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep 17(9):68","journal-title":"Curr Urol Rep"},{"key":"2349_CR11","unstructured":"Shariat SF, Stenzl A. Upper tract urothelial carcinoma (UTUC) a joint SIU-ICUD International Consultation. Published by the Soci\u00e9t\u00e9 Internationale d\u2019Urologie (SIU) \n                    http:\/\/www.siu-urology.org\n                    \n                  . 2013"},{"issue":"5","key":"2349_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","volume":"60","author":"G Giannarini","year":"2011","unstructured":"Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE (2011) Antegrade perfusion with bacillus Calmette\u2013Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 60(5):955\u2013960","journal-title":"Eur Urol"},{"issue":"9","key":"2349_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1089\/end.2016.0871","volume":"31","author":"M Metcalfe","year":"2017","unstructured":"Metcalfe M, Wagenheim G, Xiao LC et al (2017) Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes. J Endourol 31(9):946\u2013953","journal-title":"J Endourol"},{"issue":"8","key":"2349_CR14","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette\u2013Guerin. Urol Oncol-Semin Ori 31(8):1635\u20131642","journal-title":"Urol Oncol-Semin Ori"},{"issue":"6","key":"2349_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1756287215599694","volume":"7","author":"DH Tang","year":"2015","unstructured":"Tang DH, Chang SS (2015) Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol 7(6):351\u2013364","journal-title":"Ther Adv Urol"},{"issue":"3","key":"2349_CR16","first-page":"244","volume":"4","author":"FC Rundstedt von","year":"2015","unstructured":"von Rundstedt FC, Lerner SP (2015) Bacille\u2013Calmette\u2013Guerin non-responders: how to manage. Transl Androl Urol 4(3):244\u2013253","journal-title":"Transl Androl Urol"},{"key":"2349_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000052376","volume":"37","author":"DL Lamm","year":"2000","unstructured":"Lamm DL (2000) Preventing progression and improving survival with BCG maintenance. Eur Urol 37:9\u201315","journal-title":"Eur Urol"},{"issue":"16","key":"2349_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34(16):1935","journal-title":"J Clin Oncol"},{"issue":"1","key":"2349_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","volume":"172","author":"J Palou","year":"2004","unstructured":"Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H (2004) Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol 172(1):66\u201369","journal-title":"J Urol"},{"issue":"2 Pt 1","key":"2349_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00005392-199608000-00011","volume":"156","author":"JA Martinez-Pineiro","year":"1996","unstructured":"Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L (1996) Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 156(2 Pt 1):377\u2013385","journal-title":"J Urol"},{"issue":"3","key":"2349_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","volume":"58","author":"LG Luciani","year":"2001","unstructured":"Luciani LG, Neulander E, Murphy WM, Wajsman Z (2001) Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58(3):376\u2013379","journal-title":"Urology"},{"issue":"5","key":"2349_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","volume":"21","author":"JS Lam","year":"2003","unstructured":"Lam JS, Benson MC, O\u2019Donnell MA et al (2003) Bacillus Calmete\u2013Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21(5):354\u2013360","journal-title":"Urol Oncol"},{"issue":"2","key":"2349_CR23","first-page":"1790","volume":"10","author":"SP Punnen","year":"2003","unstructured":"Punnen SP, Chin JL, Jewett MA (2003) Management of bacillus Calmette\u2013Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy. Can J Urol 10(2):1790\u20131795","journal-title":"Can J Urol"},{"issue":"3","key":"2349_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/0974-7796.115746","volume":"5","author":"OM Aboumarzouk","year":"2013","unstructured":"Aboumarzouk OM, Somani B, Ahmad S, Nabi G, Townell N, Kata SG (2013) Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann 5(3):184\u2013189","journal-title":"Urol Ann"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2349-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T19:19:17Z","timestamp":1558811957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2349-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2349"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2349-9","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,26]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A. Kamat is a consultant to the following companies; Photocure, Telesta Therapeutics, Sanofi, Merck, Abbott Molecular, Theralase, Heat Biologics, Spectrum Pharmaceuticals and Oncogenix and has received research funding from FKD Industries; In addition, A. Kamat has a patent CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy pending. J. Karam is a consultant to the following companies: Pfizer, EMD Serono and Novartis. C. Dinney is a paid consultant to FKD Therapies. The corresponding author is a consultant to the following companies: Taris, Urogen, and Peloton Therapeutics and has received research funding from AT&T Foundation and Specialized Program in Oncology Research (SPORE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review does not involve human subjects and meets Helsinki declaration for protection of human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}